CN Patent

CN118724806A — 氘化化合物和其用途

Assigned to Aldeyra Therapeutics Inc · Expires 2024-10-01 · 2y expired

What this patent protects

本申请涉及氘化化合物和其用途。本发明提供通过使用伯胺清除如MDA和HNE等毒性醛来治疗、预防发病机制中涉及醛毒性的疾病、病症或病状和/或降低其风险，所述疾病、病症或病状包括眼部病症、皮肤病症、与糜烂性毒剂的有害效应相关的病状，以及自体免疫、发炎、神经和心血管疾病。

USPTO Abstract

本申请涉及氘化化合物和其用途。本发明提供通过使用伯胺清除如MDA和HNE等毒性醛来治疗、预防发病机制中涉及醛毒性的疾病、病症或病状和/或降低其风险，所述疾病、病症或病状包括眼部病症、皮肤病症、与糜烂性毒剂的有害效应相关的病状，以及自体免疫、发炎、神经和心血管疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN118724806A
Jurisdiction
CN
Classification
—
Expires
2024-10-01
Drug substance claim
No
Drug product claim
No
Assignee
Aldeyra Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.